Immuneering (IMRX) Share-based Compensation (2020 - 2026)

Immuneering's Share-based Compensation history runs 7 years deep, the most recent figure standing at $1.6 million for Q1 2026.

• On a quarterly basis, Share-based Compensation fell 3.29% year-over-year to $1.6 million in Q1 2026; TTM through Mar 2026 was $6.3 million, a 6.9% decrease from a year earlier, with the FY2025 full-year figure at $6.3 million, down 2.93% from the prior year.
• Share-based Compensation held at $1.6 million in Q1 2026 per IMRX's latest filing, from $1.6 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $1.7 million in Q4 2024 and bottomed at $897650.0 in Q1 2022.
• The 5-year median for Share-based Compensation is $1.5 million (2023), against an average of $1.4 million.
• Across the five-year window, Share-based Compensation surged 392.61% in 2022 and slipped 11.22% in 2025, its largest moves.
• Year by year, Share-based Compensation stood at $1.0 million in 2022, then surged by 56.52% to $1.6 million in 2023, then increased by 5.13% to $1.7 million in 2024, then fell by 5.04% to $1.6 million in 2025, then decreased by 0.07% to $1.6 million in 2026.
• Per Business Quant, the three latest IMRX Share-based Compensation figures stand at $1.6 million (Q1 2026), $1.6 million (Q4 2025), and $1.5 million (Q3 2025).